No one can get a bivalent vaccine, no one can get a nine-valent vaccine. On April 29, 2018, Mershadong announced that the nine-valent HPV vaccine had been approved for market in China. The vaccine is suitable for women aged 16 to 26 years, using a three-dose immunization program.
Since then, domestic nine-valent HPV vaccine has been in short supply. In contrast, bivalent HPV vaccines with higher cost-effectiveness were not available. Nurses at a health clinic in a community health service center in Beijing said that consultants hung up immediately when they heard that only bivalent vaccines were available. More netizens speculate that vaccine manufacturers are engaged in hunger marketing. In response, vaccine manufacturer Merchant did not respond.
Industry insiders have analyzed that the reason why the nine-valent HPV vaccine is so popular is largely due to the following mentality of the vaccinators, suitable, inappropriate to fight, thus exacerbating the shortage of the vaccine supply.
Domestic Continuous Shortage of Supply and Demand
Beijing Out of Stock Shenzhen Yao
Call again after March 15. Staff of the Community Health Service Center of Exhibition Road in Xicheng District of Beijing said that at present, no reservation for the nine-valent HPV vaccine was accepted, only the two-valent vaccine can be used. The vaccination clinic of Xicheng District Financial Street Community Health Service Center can now accept the appointment, but the outpatient nurses said that although the appointment was made, there were more than 1000 people in front of it. They did not know when and how many needles could be delivered this month, so they could not tell the specific vaccination time.
On February 26, the results of the second phase of the Nine-valent HPV vaccine in Shenzhen in 2019 were announced. According to data released by Shenzhen Health and Health Commission, a total of 84615 valid applicants participated in the roll call, with 2203 number sources, with a winning rate of 2.6%. In the previous period, the rate of successful signing was only 0.78%.
In February, the Center for Disease Control and Prevention in Zigong, Sichuan, issued a notice suspending the booking of a nine-valent HPV vaccine. According to the notice, the shortage of nine-valent cervical cancer vaccine corresponds to the urgent needs of female friends in the city. It is expected that this years arrival will be difficult to meet the current booking population. Therefore, the booking is suspended until the current reserved population has completed the vaccination before making an open booking.
Intermediary Price Increase Over 3000 Yuan
Manufacturers Suspected of Hunger Marketing
The shortage of nine-price HPV vaccine has created an intermediary platform specially for docking hospitals and consumers and earning service fees. Some intermediaries pass priority vaccination messages through Wechat public numbers, microblogs or Taobao online stores.
According to the customer service of a vaccination intermediary platform, the Booker can go to the designated hospital in the city for vaccination after paying the order online. The price of the three needles is 6500 yuan. The cost of three injections in public hospitals was 3369 yuan. Even if it costs 3141 yuan more, its not an express ticket. According to the customer service, the Booker will pay the full amount now, and will not start the injection until at least June this year.
At present, there are three kinds of HPV vaccines on the market, namely bivalent, tetravalent and nine-valent. In China, HPV vaccines are all imported. The producers of bivalent vaccines are GlaxoSmithKline in the United Kingdom, and the producers of tetravalent and ninth-valent vaccines are Merchant in the United States.
According to a nurse in an outpatient vaccination clinic, tetravalent vaccines were also very popular when they were just on the market. They were often out of stock, but six months later the goods came up and qualified vaccines could be called when they arrived. But nearly a year after its launch, the serious shortage of nine-valent vaccines has not been alleviated. Some netizens questioned that this is not the manufacturers hunger marketing means? In response, Beijing Youth Daily reporters contacted the media center of Mershadong (China), but as of press release, Mershadong did not respond.
Short listing time and long production cycle
According to an insider from a multinational vaccine manufacturer, after the introduction of the tetravalent HPV vaccine in that year, its expected output and production capacity are matched, so the supply of the vaccine will keep up within six months. Nine-valent vaccines, on the other hand, have a very short approval cycle, which takes only eight days from application to approval. In addition, the demand for nine-valent vaccines in the Chinese market has increased dramatically, which has caught manufacturers off guard. It is reported that nine-price HPV vaccine manufacturer only one Mershadong, and in the face of global supply in more than 70 countries, its production capacity can not immediately keep up.
In addition, according to an insider engaged in vaccine production, the vaccine production cycle is very long, which requires production, quality control, testing release in the country of origin, testing release in China. It will take at least one year for the four procedures to come down.
The industry also said that the best age for the use of the nine-valent HPV vaccine should be at puberty. However, due to frequent reports of vaccine shortages, more elderly women are motivated to get vaccinated, thus increasing market demand and supply gap. Ms. Han, a Beijing resident, said that she heard that the nine-valent HPV vaccine could prevent the most HPV viruses. She immediately wanted to vaccinate both her 48-year-old daughter and her 20-year-old daughter, but only after consultation did she know that her age had exceeded the vaccination age.
Bivalent and tetravalent are equally effective
Recognition of Nine Prices as Cognitive Bias
The World Health Organization clearly pointed out in 2017 that there is no difference in the efficacy and efficacy of bivalent, tetravalent and nine-valent vaccines in the prevention of HPV-related cervical cancer of type 16 and 18 from the perspective of public health. All three vaccines can prevent most of the related cancers. Disease prevention experts believe that although bivalent HPV vaccines only target the infection of viruses 16 and 18, current studies have shown that 70% of cervical cancer is related to these two viruses. Therefore, it is not necessary to focus on the nine-valent HPV vaccine, and in terms of cost-effectiveness, the two-valent HPV vaccine is much higher than the nine-valent HPV vaccine. Nowadays, the vaccination of nine-valent HPV vaccine in the trumpet and queue can be said to be a cognitive bias of the public. The expert said.
The World Health Organization (WHO) issued its opinion on January 24 that human papillomavirus (HPV) vaccines are the most effective if they are inoculated before they are exposed to the virus. WHO therefore recommends vaccination for most girls aged 9-14 who have not yet started sexual activity. The best way to prevent cervical cancer for women over 30 years old is to screen and treat precancerous lesions every year. WHO emphasizes that cervical cancer vaccine cannot replace cervical cancer screening.
Liu Peicheng, director of media affairs of Beijing Kexing Biological Products Co., Ltd. and standing member of Health Education and Promotion Committee of Hunan Preventive Medical Association, pointed out that about 80% of women will be infected or exposed to HPV in their lifetime. In most cases, the infected HPV will be cleared automatically by the bodys immune system within 6 to 12 months, which is called transient infection in medicine; only a small number of people will continue to be infected, in this case it is possible to develop cervical cancer. Even women experiencing persistent HPV infection need not worry too much, because from persistent HPV infection to precancerous lesions to cervical cancer, the process takes years to more than a decade, during which there is enough time to prevent cervical cancer.
Source: Yang Yi_NBJ10647, Responsible Editor of Beijing Youth Daily